ライフサイエンスコーパス: D2 receptor antagonist

1 t of breast cancer, and (-)-IBZM, a dopamine D2 receptor antagonist.

2 nsitive, calcium dependent, and blocked by a D2 receptor antagonist.

3 ) and to systemic administration of DA D1 or D2 receptor antagonists.

4 ra-HPC carbachol or NMDA are not reversed by D2 receptor antagonists.

5 vity (S2 group) or with predominant dopamine D2 receptor antagonist activity (D2 group; HBBM, 40 mg,

6 ng task under the influence of either the DA D2 receptor antagonist amisulpride (400 mg), the NMDA re

7 and placebo controlled administration of the D2-receptor antagonist amisulpride.

8 ocker, was ineffective, as were sulpiride, a D2-receptor antagonist, and tertiapin, a G protein-coupl

9 a typical antipsychotic drug haloperidol, a D2 receptor antagonist, at a dose of 0.1 mg/kg, to incre

10 A D1, but not a D2, receptor antagonist attenuated both the C/L-DOPA-ind

11 ific D1 receptor agonist, SKF38393, no D1 or D2 receptor antagonists blocked the effect.

12 Intrashell microinfusion of a D1, but not a D2 receptor antagonist, blocks ICSS.

13 ty, a group of rats received the dopamine D1/D2 receptor antagonist cis-flupenthixol (0.5 mg/kg) 30 m

14 Both D1 and D2 receptor antagonists decreased the hyperactivity seen

15 acologic PRL mobilization using the dopamine D2 receptor antagonist domperidone prevented HCC in tumo

16 tor antagonist SCH 23390 (10 microm), or the D2 receptor antagonist eticlopride (20 microm).

17 The action of dopamine was blocked by the D2 receptor antagonist eticlopride, whereas a D1/5 antag

18 opamine D1 receptor agonist SKF-38393 or the D2 receptor antagonist eticlopride.

19 D(1) receptor antagonist SCH23390 or the DA D2 receptor antagonist eticlopride.

20 the 5-HT1A receptor agonist, 8-OH-DPAT, the D2 receptor antagonist, eticlopride, and the D1 receptor

21 The D2 receptor antagonist, eticlopride, blocked the ibogain

22 bilateral intra-amygdaloid infusions of the D2 receptor antagonist, eticlopride, on the acquisition

23 dopamine transporter inhibitor nisoxetine or D2 receptor antagonist flupentixol significantly increas

24 examined the effect of a single dose of the D2 receptor antagonist haloperidol (2 mg) on temporal di

25 examined the effects of a single dose of the D2 receptor antagonist haloperidol on temporal discounti

26 social learning is modulated by the dopamine D2 receptor antagonist haloperidol when social informati

27 f the dopamine precursor L-dopa, 2 mg of the D2 receptor antagonist haloperidol, and placebo.

28 anaesthesia) administration of the dopamine D2 receptor antagonist haloperidol, but not raclopride (

29 the typical antipsychotic drug and dopamine D2 receptor antagonist haloperidol.

30 change the early-gene response elicited by a D2 receptor antagonist (haloperidol).

31 Interestingly, dopamine D1 and D2 receptor antagonists have opposite effects on plastic

32 s methylphenidate and sulpiride, a selective D2 receptor antagonist, increased cognitive motivation m

33 e antipsychotic drug raclopride, a selective D2 receptor antagonist, increased phosphorylation of DAR

34 D1 receptor antagonist--but not dopaminergic D2 receptor antagonist--inhibited the TSD-mediated incre

35 Preincubation of (+)-butaclamol, a D2 receptor antagonist, inhibits both DA-stimulated tyro

36 effects whereas subeffective doses of the DA D2 receptor antagonist, L-741,626, rescued cocaine's abi

37 temic administration of a selective dopamine D2 receptor antagonist partially blocked the effects eli

38 atment for Tourette syndrome and primarily a D2 receptor antagonist, prevented D1 stimulation with SK

39 ctively, given that pretreatment with D1 and D2 receptor antagonists prevents the respective actions

40 Pretreatment with the dopamine D2 receptor antagonist raclopride (1mg/kg, ip) failed to

41 llenging them with the preferential dopamine D2 receptor antagonist raclopride and D1 receptor antago

42 usion of 10 microg (but not 2 microg) of the D2 receptor antagonist raclopride facilitated nursing bu

43 he reticulospinal cell responses whereas the D2 receptor antagonist raclopride increased the response

44 by their altered sensitivity to the dopamine D2 receptor antagonist raclopride.

45 The dopamine D2 receptor antagonist, raclopride, attenuated the actio

46 Positron emission tomography with the DA D2 receptor antagonist radiotracer [11C]raclopride detec

47 dol (0.2 mg/kg), relatively selective D1 and D2 receptor antagonists, respectively, blocked the AMPH-

48 Interestingly, 1 mum sulpiride, a D2 receptor antagonist, restored tLTP.

49 nist, SR141716A (5 mg/kg, i.p.), or dopamine D2 receptor antagonist, S(-)-raclopride (5 mg/kg, i.p.)

50 ter cAMP levels in other systems); 2) D1 and D2 receptor antagonists (SCH 23390, eticlopride, raclopr

51 rats were injected with the selective D1 or D2 receptor antagonists SCH23390 or eticlopride prior to

52 sing bilateral reverse microdialysis, D1 and D2 receptor antagonists (SCH23390, sulpiride) and the DA

53 We used the D2 receptor antagonist sulpiride and mice lacking the D2

54 This effect was completely reversed by the D2 receptor antagonist sulpiride but not by SCH 23390, a

55 The D2 receptor antagonist sulpiride reduces accuracy due to

56 By contrast, amphetamine and the D2 receptor antagonist sulpiride were without significan

57 hat was prevented by coadministration of the D2 receptor antagonist sulpiride.

58 receptor antagonist SCH23390 but not by the D2 receptor antagonist sulpiride.

59 stered methylphenidate, placebo or selective D2 receptor antagonist sulpiride.

60 The dopamine D2-receptor antagonist sulpiride decreases spontaneous l

61 Dopamine (D2) receptor antagonists were evaluated (Haloperidol [0.

62 ncer properties that are distinct from other D2 receptor antagonists widely used for the treatment of

63 It is the first non-D2 receptor antagonist with clear antipsychotic effects

64 n humans, we combined sulpiride, a selective D2 receptor antagonist, with the dopamine precursor l-DO

65 These included four dopamine D2 receptor antagonists, with D2 receptors having previo